UCB (OTCMKTS:UCBJF) Shares Gap Down – Here’s What Happened

UCB SA (OTCMKTS:UCBJF) gapped down prior to trading on Tuesday . The stock had previously closed at $313.72, but opened at $294.11. UCB shares last traded at $310.09, with a volume of 8 shares changing hands.

Analysts Set New Price Targets

Several brokerages have issued reports on UCBJF. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a report on Monday, February 16th. Wolfe Research initiated coverage on shares of UCB in a research note on Monday, February 23rd. They set an “outperform” rating on the stock. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, UCB has an average rating of “Buy”.

UCB Trading Up 6.1%

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm’s 50 day moving average is $294.74 and its 200-day moving average is $297.92.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.